|
T7317 |
CU-CPT-9a
|
|
TLR
|
|
CU-CPT-9a is a potent TLR8 inhibitor (IC50 : 0.5 nM), that suppresses TLR8-mediated proinflammatory signaling in various cell lines and human primary cells- |
|
T7347 |
CU-CPT-8m
|
TLR8-specific antagonist |
TLR
|
|
CU-CPT-8m (TLR8-specific antagonist) is an toll-like receptor 8 (TLR8) antagonist (IC50 : 67 nM) |
|
T27076 |
8-Cyclopentyl-1,3-dimethylxanthine
|
CPT |
Adenosine Receptor
|
|
8-Cyclopentyl-1,3-dimethylxanthine (CPT) is a potent antagonist of adenosine A1 receptor. |
|
T22698 |
TLR3-IN-1
|
CU CPT 4a |
TLR
|
|
TLR3-IN-1 (CU CPT 4a) is a selective TLR3 inhibitor (IC50: 3.44 μM in RAW 264.7 cells). It can inhibit TLR3/dsRNA complex-mediated downstream signaling pathways and inhibit the production of TNF-α and IL-1β in whole cell... |
|
T41018 |
CPT-157633
|
|
|
|
CPT-157633 is a difluoro-phosphonomethyl phenylalanine derivative that acts as a potent inhibitor of the enzyme PTP1B. It effectively prevents the development of glucose intolerance induced by binge drinking. |
|
T24610 |
Pegamotecan
|
Prothecan,PEG-camptothecin,PEG-beta-CPT |
Topoisomerase
|
|
Pegamotecan (PEG-camptothecin) is a topoisomerase I (TOP1) inhibitor with anticancer activity, and it is used in the treatment of esophageal, non-small cell lung and pancreatic cancers. |
|
T7302 |
CU-CPT9b
|
CU-CPT-9b,TLR8-specific antagonist 1 |
TLR
|
|
CU-CPT9b (TLR8-specific antagonist 1) is an antagonist of toll-like receptor 8 (TLR8; Kd = 21 nM). It inhibits activation of NF- B induced by the TLR8 agonist R-848 in TLR8-overexpressing HEK-Blue cells with an IC50 valu... |
|
T38696 |
Rp-8-CPT-cAMPS
|
|
|
|
Rp-8-CPT-cAMPS is a powerful and competitive antagonist of cAMP-induced activation of cAMP-dependent protein kinase (PKA) I and II. Acting as a potent cAMP analog, Rp-8-CPT-cAMPS exhibits a preference for site A of RI ov... |
|
T38694 |
Sp-8-CPT-cAMPS
|
|
|
|
Sp-8-CPT-cAMPS is a powerful and specific cAMP analog that activates cAMP-dependent protein kinase A (PKA I and PKA II) selectively and effectively. It exhibits a 153-fold preference for site A of RI over site A of RII, ... |
|
T36678 |
Rp-8-CPT-cAMPS sodium
|
|
|
|
Rp-8-CPT-cAMP is a structural combination of the lipophilic and non-hydrolyzable cAMP analogs, 8-CPT-cyclic AMP and Rp-cyclic AMPS .[1] It functions as a site-selective inhibitor of protein kinase A (PKA) type I and II, ... |
|
T22014 |
8-CPT-2Me-cAMP, sodium salt
|
|
|
|
8-CPT-2Me-cAMP sodium is a sodium salt compound that selectively activates exchange proteins activated by cAMP (Epac). These Epac proteins are cAMP-sensitive guanine nucleotide exchange factors (GEFs) responsible for act... |
|
T21705 |
8-CPT-Cyclic AMP (sodium salt)
|
|
|
|
8-CPT-Cyclic AMP (8-CPT-cAMP) sodium functions dually as a selective activator of cyclic AMP-dependent protein kinase (PKA) and as a potent inhibitor of the cyclic GMP-specific phosphodiesterase (PDE VA), demonstrating a... |
|
T73422 |
CPT-Se4
|
|
Topoisomerase
|
|
CPT-Se4, a seleno-derivative of Camptothecin (CPT), exhibits enhanced efficacy in cancer cell eradication and tumor suppression. It reduces the GSH/GSSG balance and total thiol content while increasing ROS concentrations... |
|
T73421 |
CPT-Se3
|
|
Topoisomerase
|
|
CPT-Se3, a camptothecin (CPT) seleno-derivative, exhibits enhanced anticancer efficacy by effectively killing cancer cells and hindering tumor proliferation. This compound diminishes the GSH/GSSG ratio and total thiols w... |
|
T10899 |
CU-CPT17e
|
|
TLR
|
|
CU-CPT17e is a potent agonist of TLR(TLR3, TLR8, and TLR9). |
|
T15020 |
CU-CPT22
|
|
TLR
|
|
CU-CPT22 is the first probe for the complex between toll-like receptors TLR1 and TLR2. CU-CPT22 binds at the interface of TLR1 and TLR2 (IC50 = 0.58 μM). It competes with the synthetic triacylated lipoprotein (Pam3CSK4) ... |
|
T4535 |
Etomoxir sodium salt
|
(R)-Etomoxir sodium salt,Na salt,Etomoxir |
Apoptosis
,
Others
|
|
Etomoxir sodium salt ((R)-Etomoxir sodium salt) is a carnitine palmitoyltransferase 1a (CPT-1a) inhibitor that blocks fatty acid synthesis. Etomoxir sodium salt has antitumor activity. |
|
T8344 |
CPTH2
|
|
Apoptosis
,
Histone Acetyltransferase
|
|
CPTH2 is a histone acetyltransferase inhibitor modulating Gcn5 network. |
|
T64643 |
Rh2(S-TCPTAD)4
|
|
|
|
Rh2(S-TCPTAD)4 is a useful organic compound for research related to life sciences and the catalog number is T64643. |
|
T40879 |
7-MAD-MDCPT
|
|
|
|
7-MAD-MDCPT, a Camptothecin analog, is a toxin payload in antibody drug conjugates (ADCs). |
|
T39941 |
MP-PEG4-Val-Lys-Gly-7-MAD-MDCPT
|
MP-PEG4-Val-Lys-Gly-7-MAD-MDCPT |
|
|
MP-PEG4-Val-Lys-Gly-7-MAD-MDCPT is a Camptothecin-linker. MP-PEG4-Val-Lys-Gly-7-MAD-MDCPT is a drug-linker conjugate for antibody-drug conjugate (ADC). |
|
T74751 |
Br-Val-Ala-NH2-bicyclo[1.1.1]pentane-7-MAD-MDCPT
|
|
|
|
Br-Val-Ala-NH2-bicyclo[1.1.1]pentane-7-MAD-MDCPT (Formula V) is a conjugate comprising a potent topoisomerase I inhibitor linked to an antibody agent conjugate (ADC) [1] through a specialized linker. |
|
T81752 |
MP-PEG8-Val-Lys-Gly-7-MAD-MDCPT
|
|
|
|
MP-PEG8-Val-Lys-Gly-7-MAD-MDCPT is an agent-linker conjugate designed for antibody-drug conjugate (ADC) applications, with potential use in cancer and autoimmune disease research. |
|
T22536 |
8-pCPT-2-O-Me-cAMP-AM
|
|
Others
|
|
Epac activator |
|
T25409 |
FCPT
|
|
|
|
FCPT is an ATP competitive kinesin-5 inhibitor. |
|
T78569 |
CPT2
|
Carnitine palmitoyltransferase 2 |
Apoptosis
|
|
Carnitine palmitoyltransferase 2 (CPT2), an enzyme involved in fatty acid oxidation, serves as a prognostic biomarker for colorectal cancer (CRC). Overexpression of CPT2 activates phosphorylated p53, enhancing its expres... |
|
T77873 |
NH2-bicyclo[1.1.1]pentane-7-MAD-MDCPT hydrochloride
|
|
Topoisomerase
|
|
Compound I, NH2-bicyclo[1.1.1]pentane-7-MAD-MDCPT hydrochloride, is a topoisomerase I inhibitor that demonstrates effective antibody-drug conjugate (ADC) activity both in vivo and in vitro, with delivery to cells facilit... |
|
T22550 |
ACPT-II
|
|
Others
|
|
metabotropic receptor antagonist |
|
T22693 |
CPTH2 (hydrochloride) (357649-93-5 free base)
|
CPTH2 (hydrochloride) |
Others
|
|
CPTH2 is an inhibitor of the HAT activity of Gcn5. |
|
T22549 |
ACPT-I
|
|
Others
|
|
Agonist for group III mGlu receptors |
|
T72756 |
Gly-7-MAD-MDCPT
|
|
|
|
Gly-7-MAD-MDCPT is an anticancer agent. Gly-7-MAD-MDCPT is a Camptothecin compound, it shows cytotoxicity to various cancer cells with IC 50 values of 10-1000 nM [1] . |
|
T74750 |
NH2-bicyclo[1.1.1]pentane-7-MAD-MDCPT
|
|
|
|
Compound I, NH2-bicyclo[1.1.1]pentane-7-MAD-MDCPT, is a topoisomerase I inhibitor with the capability for targeted delivery to cells via conjugated antibodies. It exhibits effective ADC activity both in vivo and in vitro... |
|
T11978 |
McN3716
|
NSC359682,Methyl palmoxirate |
Mitochondrial Metabolism
,
CPT
|
|
|
|
T4535L |
Etomoxir
|
(R)-(+)-Etomoxir |
Antioxidant
,
CPT
|
|
Etomoxir is a carnitine palmitoyltransferase 1a (CPT-1a) inhibitor that inhibits fatty acid oxidation by inhibiting CPT-1a and inhibits palmitate oxidation in humans, rats, and guinea pigs. Etomoxir has an inhibitory eff... |
|
T12408 |
Perhexiline maleate
|
|
Others
,
Mitochondrial Metabolism
|
|
Perhexiline maleate is an orally active inhibitor of CPT1 and CPT2 that reduces fatty acid metabolism. The IC50 values of perhexiline maleate against rat heart and liver CPT 1 were 77 and 148 μM, respectively. |
|
T9088 |
Topovale
|
ARC111,ARC 111,ARC-111,Topoval |
Topoisomerase
|
|
Topovale (ARC111) is a potent inhibitor of topoisomerase I. Topovale inhibits hypoxia-mediated accumulation of hypoxia-inducible factor-1alpha. Topovale exhibited low nM cytotoxicity against a panel of cancer cells. Topo... |
|
T14454 |
Azido-PEG5-acid
|
|
Others
|
|
Azido-PEG5-acid is a non-cleavable 5 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs), such as the conjugate CPT-APO (CPT: Camptothecin. |
|
T27831 |
Lifibrate
|
|
|
|
Lifibrate is an inhibitor of cholinephosphotransferase (CPT), phosphatidyl-N,N-dimethylethanolamine N-methyltransferase (PDE-NMT), and phosphatidyl-N-methylethanolamine N-methyltransferase (PME-NMT). |
|
T38474 |
CL2-MMT-SN38
|
CL2-MMT-SN38 |
|
|
CL2-MMT-SN38 is a derivative of SN-38, which is a potent anticancer agent and the active metabolite of Irinotecan (CPT-11), a Topoisomerase I inhibitor. |
|
T78069 |
RPR132595A hydrochloride
|
NPC hydrochloride |
Drug Metabolite
|
|
RPR132595A (NPC) hydrochloride, an active metabolite of CPT-11, is produced via cytochrome P-450 3A4 (CYP3A4) metabolism and is ultimately eliminated via urinary excretion [1]. |
|
T19553 |
RPR132595A
|
NPC |
Others
|
|
RPR132595A is an active CPT-11 metabolite, it is generated by cytochrome P-450 3A4 (CYP3A4). |
|
T70380 |
ZBH-1205
|
|
|
|
ZBH-1205 is a novel camptothecin derivative, revealing potent antitumor activities mainly through cell apoptosis pathway, being more effective than cpt-11 and sn38 at inhibiting topoismerase-1 |
|
T68196 |
Aminocarnitine
|
|
|
|
Aminocarnitine is an inhibitor of fatty acid oxidation that acts as a hypoglycemic and antiketogenic compound. It alters lipidic metabolism by inhibiting carnitine acetyltransferase (CAT) and carnitine palmitoyltransfera... |
|
T74494 |
Antitumor agent-63
|
|
|
|
Antitumor Agent-63 (Compound 40), a 20 (S)-O-linked camptothecin (CPT) glycoconjugate, serves as a non-toxic antitumor agent showing high stability and very weak direct inhibition of topoisomerase I (Topo I) [1], demonst... |
|
T78711 |
A011
|
|
ATM/ATR
|
|
A011, a potent and selective ataxia-telangiectasia mutated (ATM) inhibitor, exhibits an IC50 of 1.0 nM and triggers apoptosis as well as G2/M phase cell cycle arrest when combined with CPT-11, displaying notable antitumo... |
|
T73829 |
Malonyl CoA
|
|
|
|
Malonyl CoA serves as a substrate in fatty acid biosynthesis while inhibiting fatty acid oxidation. It also acts as a reversible inhibitor of mitochondrial carnitine palmitoyltransferase (CPT) 1 [1] [2]. |
|
T77816 |
Deruxtecan analog 2
|
|
|
|
Deruxtecan Analog 2 (example 9 P3), a Deruxtecan derivative, serves as an agent-linker conjugate integrating Camptothecin (CPT), a Topo I inhibitor active against colorectal, breast, lung, and ovarian cancers, with a dis... |
